<SEC-DOCUMENT>0001493152-21-031904.txt : 20211217
<SEC-HEADER>0001493152-21-031904.hdr.sgml : 20211217
<ACCEPTANCE-DATETIME>20211217172258
ACCESSION NUMBER:		0001493152-21-031904
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20211217
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211217
DATE AS OF CHANGE:		20211217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		211502726

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ABEO="http://abeonatherapeutics/20211217">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_ABEO_abeonatherapeutics_20211217 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20211217_20211217 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20211217.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-12-17to2021-12-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-17</xbrli:startDate>
        <xbrli:endDate>2021-12-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_906_edei--DocumentType_c20211217__20211217_zz7FFZZ3HxXk"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>PURSUANT
TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Date
of report (Date of earliest event reported): <b><span id="xdx_908_edei--DocumentPeriodEndDate_c20211217__20211217_zN5M2R1WIBR1"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 17, 2021</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20211217__20211217_zxFEa5oV1rN1"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityRegistrantName">ABEONA
THERAPEUTICS INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20211217__20211217_zMbtVv9Xkebd"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityFileNumber_c20211217__20211217_zEad2JyYw7pl"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20211217__20211217_z9FoYXOWr1Sg"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">of
    incorporation)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">File
    Number)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20211217__20211217_zTTFqEFnX78i"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityAddressAddressLine1">1330
Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20211217__20211217_zQ0kqygzpE06"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityAddressAddressLine2">33rd Floor</ix:nonNumeric></span>, </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20211217__20211217_zQhE0G8SkLEa"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20211217__20211217_zmVkPzHBmQfj"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20211217__20211217_zfXRXkUFVG1f"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric> </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--CityAreaCode_c20211217__20211217_zqwWoFPNq8bi"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>
<span id="xdx_90A_edei--LocalPhoneNumber_c20211217__20211217_zkpM0BL8xOKj"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:LocalPhoneNumber">813-4701</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">N/A</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--WrittenCommunications_c20211217__20211217_z7tgYN9o2tNk"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SolicitingMaterial_c20211217__20211217_zW2TzDLguZki"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20211217__20211217_zMH1fJD2JvK7"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20211217__20211217_zV3cglsGf9Oi"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of Each Class</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--Security12bTitle_c20211217__20211217_zHtxxl8OA0fd"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--TradingSymbol_c20211217__20211217_zF9rw9Bzn9Lc"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><span><span id="xdx_906_edei--SecurityExchangeName_c20211217__20211217_zZ7XxAg99eb2"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    <span>Capital</span> Market</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20211217__20211217_zJwH64IPpGf8"><ix:nonNumeric contextRef="From2021-12-17to2021-12-17" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    8.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span>On
December 17, 2021, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Cantor Fitzgerald
&amp; Co., as representative of the several underwriters named on Schedule A thereto (the &#8220;Underwriters&#8221;) relating to the
issuance and sale of (a) 44,700,000 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;), and (b) warrants to purchase
44,700,000 shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;) to the Underwriters (the &#8220;Offering&#8221;).
Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined public offering price
of $0.39, less underwriting discounts and commissions. The Warrants have an exercise price of $0.39 per share, are exercisable immediately,
and will expire five years following the date of issuance. The Underwriting Agreement contains customary representations and warranties,
conditions to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities
under the Securities Act of 1933, as amended.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company estimates that net proceeds from the Offering will be approximately $17.5 million, before deducting underwriting discounts and
commissions and estimated Offering expenses. The Company expects the Offering to close on December 21, 2021, subject to customary closing
conditions. The Offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-256850) previously filed
by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 7, 2021, amended on August 27, 2021 and October
19, 2021, and declared effective by the SEC on October 22, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Underwriting Agreement and form of Warrant are filed as Exhibits 1.1 and 4.1, respectively, to this Current Report on Form 8-K and the
foregoing descriptions of the terms of the Underwriting Agreement and the Warrant are qualified in its entirety by reference to such
exhibits. A copy of the opinion of Morgan, Lewis &amp; Bockius LLP relating to the legality of the issuance and sale of the Shares and
the Warrants in the Offering is filed with this Current Report on Form 8-K as Exhibit 5.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
December 17, 2021, the Company issued a press release announcing the pricing of the Offering. The full text of the press release is filed
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><b>Item 9.01.</b><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(d)
Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Exhibit
    No.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex1-1.htm">Underwriting Agreement, dated December 17, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-1.htm">Form of Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm">Opinion of Morgan, Lewis &amp; Bockius LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm">Consent of Morgan, Lewis &amp; Bockius LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-1.htm">Press release dated December 17, 2021, entitled &#8220;Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants&#8221;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">Abeona Therapeutics Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Brendan M. O&#8217;Malley</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Brendan M. O&#8217;Malley</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Date:
December 17, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5FpsUROmnRUWsIqWIv8GuEmyzZZNWPZK3NLaIy8KyzLwZISZiQ2tTI8N5WeRQYtPW2iMUeEVGe8HgyLa7FMIt8GacZ2398P7AjAKDgZlNlbwEYbD2xmGVgkpiNY8TBXKWygUc9yL66hnZq6nQeqNr0LaCI1PLBr3m15hQ6idZal5D1QnZGbIhbipH+Q2JVAkcqNcP4ruDPM9ENBkmEhumrv3WdM5TA6sam9DlRvS/0QcYLklK -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>44,700,000
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants
to Purchase 44,700,000 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>UNDERWRITING
AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">499
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introductory.
</B>Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several underwriters
named in <U>Schedule A</U> (the &ldquo;<B>Underwriters</B>&rdquo;) (i) an aggregate of 44,700,000 shares (the &ldquo;<B>Offered Shares</B>&rdquo;)
of its common stock, par value $0.01 per share (the &ldquo;<B>Shares</B>&rdquo;) and (ii) 44,700,000 warrants of the Company, in the
form set forth in <U>Exhibit C</U> hereto, to purchase Shares of Common Stock (the &ldquo;<B>Warrants</B>&rdquo;). Each Offered Share
is being sold together with one Warrant; and each full Warrant is exercisable for one Share at an exercise price of $0.39 per whole share.
The Offered Shares and the Warrants to be sold by the Company are collectively referred to as the &ldquo;<B>Offered Securities</B>.&rdquo;
Cantor Fitzgerald &amp; Co. (&ldquo;<B>Cantor</B>&rdquo;) has agreed to act as representative of the several Underwriters (in such capacity,
the &ldquo;<B>Representative</B>&rdquo;) in connection with the offering and sale of the Offered Securities. To the extent there are
no additional underwriters listed on <U>Schedule A</U>, the term &ldquo;Representative&rdquo; as used herein shall mean Cantor, as Underwriter,
and the term &ldquo;Underwriters&rdquo; shall mean either the singular or the plural, as the context requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, &ldquo;<B>Warrant Shares</B>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a shelf registration
statement on Form S-3, File No. 333-256850, including a base prospectus (the &ldquo;<B>Base Prospectus</B>&rdquo;) to be used in connection
with the public offering and sale of the Offered Securities. Such registration statement, as amended, including the financial statements,
exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder (collectively, the &ldquo;<B>Securities Act</B>&rdquo;), including all documents incorporated
or deemed to be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant
to Rule 430B under the Securities Act, is called the &ldquo;<B>Registration Statement</B>.&rdquo; Any registration statement filed by
the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Securities is called
the &ldquo;<B>Rule 462(b) Registration Statement</B>,&rdquo; and from and after the date and time of filing of any such Rule 462(b) Registration
Statement the term &ldquo;Registration Statement&rdquo; shall include the Rule 462(b) Registration Statement. The preliminary prospectus
supplement dated December 16, 2021 describing the Offered Securities and the offering thereof (the &ldquo;<B>Preliminary Prospectus Supplement</B>&rdquo;),
together with the Base Prospectus, is called the &ldquo;<B>Preliminary Prospectus</B>,&rdquo; and the Preliminary Prospectus and any
other prospectus supplement to the Base Prospectus in preliminary form that describes the Offered Securities and the offering thereof
and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &ldquo;<B>preliminary
prospectus</B>.&rdquo; As used herein, the term &ldquo;<B>Prospectus</B>&rdquo; shall mean the final prospectus supplement to the Base
Prospectus that describes the Offered Securities and the offering thereof (the &ldquo;<B>Final Prospectus Supplement</B>&rdquo;), together
with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Securities or in the form first
made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. References
herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and
the Base Prospectus components of such prospectus. As used herein, &ldquo;<B>Applicable Time</B>&rdquo; is 8:00 a.m. (New York City time)
on December 17, 2021. As used herein, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule 405 under the Securities
Act, and &ldquo;<B>Time of Sale Prospectus</B>&rdquo; means the Preliminary Prospectus, as amended or supplemented immediately prior
to the Applicable Time, together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto and the pricing information
set forth on <U>Schedule C</U> hereto. As used herein, &ldquo;<B>Road Show</B>&rdquo; means a &ldquo;road show&rdquo; (as defined in
Rule 433 under the Securities Act) relating to the offering of the Offered Securities contemplated hereby that is a &ldquo;written communication&rdquo;
(as defined in Rule 405 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus
and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this
Agreement to financial statements and schedules and other information which are &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
in, or &ldquo;part of&rdquo; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary
prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed
to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference
in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base
Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements
to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus
or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;) that is or is deemed to be
incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus,
or the Prospectus, as the case may be. All references in this Agreement to (i) the Registration Statement, the Preliminary Prospectus,
any preliminary prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free
writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and
Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;) and (ii) the Prospectus shall be deemed to include any &ldquo;electronic Prospectus&rdquo;
provided for use in connection with the offering of the Offered Securities as contemplated by Section 3(n) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby confirms its agreements with the Underwriters as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1. &nbsp;Representations and Warranties of the Company.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement and as of the First Closing Date
(as hereinafter defined), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Compliance
with Registration Requirements</I>.</B> The Registration Statement has become effective under the Securities Act. The Company has complied,
to the Commission&rsquo;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop
order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. At the time the Company&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2020 (the &ldquo;<B>Annual Report</B>&rdquo;) was filed with the Commission,
or, if later, at the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements
for use of Form S-3 under the Securities Act. The documents incorporated or deemed to be incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became
effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the
Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>Disclosure</I>. </B>Each
preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by
electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S-T under the Securities Act) to
the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Securities. Each of the
Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will
comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the
Applicable Time, the Time of Sale Prospectus (including any preliminary prospectus wrapper) did not, and at the First Closing Date
(as defined in Section 2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus (including
any Prospectus wrapper), as of its date, did not, and at the First Closing Date, will not, contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding
sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the
Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with
written information relating to any Underwriter furnished to the Company in writing by the Representative expressly for use therein,
it being understood and agreed that the only such information consists of the information described in Section 9(b) below. There are
no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an
exhibit to the Registration Statement which have not been described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Free
Writing Prospectuses; Road Show</I>.</B> As of the determination date referenced in Rule 164(h) under the Securities Act, the Company
was not, is not or will not be (as applicable) an &ldquo;ineligible issuer&rdquo; in connection with the offering of the Offered Securities
pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant
to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities
Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act
or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the
requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention where required and legending,
and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and
sale of the Offered Securities did not, does not and will not include any information that conflicted, conflicts or will conflict with
the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and not superseded or modified.
Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished to you
before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or
refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the
Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Distribution
of Offering Material By the Company</I>.</B> Prior to the completion of the Underwriters&rsquo; distribution of the Offered Securities<B>,
</B>the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered
Securities other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed
and consented to by the Representative, and the free writing prospectuses, if any, identified on <U>Schedule B </U>hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>The
Underwriting Agreement</I>.</B> This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f) <I>Authorization
of the Offered Securities</I>.</B> The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement
and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully
paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights, rights of first
refusal or other similar rights to subscribe for or purchase the Offered Shares. The Warrants have been duly authorized by the
Company and, when executed and delivered by the Company, will be a valid and binding agreement of the Company, enforceable against
the Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general
equitable principles. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Warrants
in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the
Warrants in accordance therewith, will be validly issued, fully paid and nonassessable and will conform to the descriptions thereof
in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The issuance of the Warrant Shares is not subject to
any preemptive rights, rights of first refusal or other similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g) <I>No
Applicable Registration or Other Similar Rights</I>.</B> There are no persons with registration or other similar rights to have any equity
or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except
for such rights as have been duly complied with or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h) <I>No
Material Adverse Change</I>.</B> Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the
Prospectus: (i) there has been no material adverse change, or any development that could be expected to result in a material adverse
change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects,
whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity
(any such change being referred to herein as a &ldquo;<B>Material Adverse Change</B>&rdquo;); (ii) the Company and its subsidiaries,
considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation
any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered
by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or
in the aggregate, to the Company and its subsidiaries, considered as one entity, or has entered into any material transactions not in
the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material increase in
any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind
declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&rsquo;s
subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of
capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i) <I>Independent
Accountants</I>.</B> Whitley Penn LLP, which has expressed its opinion with respect to the financial statements (which term as used in
this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale
Prospectus and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange
Act, and the rules of the Public Company Accounting Oversight Board (&ldquo;<B>PCAOB</B>&rdquo;), (ii) in compliance with the applicable
requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered
public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration
to be withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j) <I>Financial
Statements</I>.</B> The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus
and the Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries
as of the dates indicated and the results of their operations, changes in stockholders&rsquo; equity and cash flows for the periods specified.
Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States
applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and guidelines
applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement,
the Time of Sale Prospectus or the Prospectus. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being
associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated
by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or
other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k) <I>Company&rsquo;s
Accounting System</I>.</B> The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of
internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s
general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement,
the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in
accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l) <I>Disclosure
Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</I>.</B> The Company has established
and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&rsquo;s
principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which
the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness
as of the end of the Company&rsquo;s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions
for which they were established. Since the end of the Company&rsquo;s most recent audited fiscal year, there have been no significant
deficiencies or material weakness in the Company&rsquo;s internal control over financial reporting (whether or not remediated) and no
change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company&rsquo;s internal control over financial reporting. The Company is not aware of any change in its internal control
over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely
to materially affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m) <I>Incorporation
and Good Standing of the Company</I>.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing
under the laws of the State of Delaware and has the corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform
its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing
in the State of Delaware and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure to so qualify could not be expected, individually or in the aggregate,
to have a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n) <I>Subsidiaries</I>.
</B>Each of the Company&rsquo;s &ldquo;subsidiaries&rdquo; (for purposes of this Agreement, as defined in Rule 405 under the Securities
Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability
company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and
authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&rsquo;s subsidiaries is duly qualified as a foreign corporation,
partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure
to so qualify could not be expected, individually or in the aggregate, to have a Material Adverse Change. All of the issued and outstanding
capital stock or other equity or ownership interests of each of the Company&rsquo;s subsidiaries have been duly authorized and validly
issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation,
association or other entity other than the subsidiaries listed in Exhibit 21 to the Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o) <I>Capitalization
and Other Capital Stock Matters</I>.</B> The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration
Statement, the Time of Sale Prospectus and the Prospectus under the caption &ldquo;Description of Our Common Stock&rdquo; (other than
for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each
case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Offered Securities and the Warrant
Shares conform in all material respects to the description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding
Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal
and state securities laws in all material respects. None of the outstanding Shares was issued in violation of any preemptive rights,
rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding
options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into
or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company&rsquo;s stock option, stock bonus and other
stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of
Sale Prospectus and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements,
options and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p) <I>Stock
Exchange Listing</I>.</B> The Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;<B>Common Stock</B>&rdquo;) is registered
pursuant to Section 12(b) or 12(g) of the Exchange Act and is listed on The Nasdaq Capital Market (the &ldquo;<B>Nasdaq</B>&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from the Nasdaq, nor has the Company received any notification that the Commission or
the Nasdaq is contemplating terminating such registration or listing. Except as disclosed in the Registration Statement, the Time of
Sale Prospectus, and the Prospectus, to the Company&rsquo;s knowledge, it is in compliance with all applicable listing requirements of
Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q) <I>Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required</I>.</B> Neither the Company nor any of its subsidiaries is
in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable,
or is in default (or, with the giving of notice or lapse of time, would be in default) (&ldquo;<B>Default</B>&rdquo;) under any indenture,
loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge
agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness)
to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective
properties or assets are subject (each, an &ldquo;<B>Existing Instrument</B>&rdquo;), except for such Defaults as could not be expected,
individually or in the aggregate, to have a Material Adverse Change. The Company&rsquo;s execution, delivery and performance of this
Agreement and the Warrants, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale
Prospectus and the Prospectus and the issuance and sale of the Offered Securities and the Warrant Shares (including the use of proceeds
from the sale of the Offered Securities as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under
the caption &ldquo;Use of Proceeds&rdquo;) (i) have been duly authorized by all necessary corporate action and will not result in any
violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar organizational documents,
as applicable, of the Company or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment
Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument
and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the
Company or any of its subsidiaries, except, in the case of (ii) above, as could not be expected, individually or in the aggregate, to
have a Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other
governmental or regulatory authority or agency, is required for the Company&rsquo;s execution, delivery and performance of this Agreement
and the Warrants and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus
and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act
and such as may be required under applicable state securities or blue sky laws or by the Financial Industry Regulatory Authority, Inc.
(&ldquo;<B>FINRA</B>&rdquo;). As used herein, a &ldquo;<B>Debt Repayment Triggering Event</B>&rdquo; means any event or condition which
gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness
(or any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r) <I>Compliance
with Laws.</I></B> The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations,
except where failure to be so in compliance could not be expected, individually or in the aggregate, to have a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s) <I>No
Material Actions or Proceedings</I>.</B> There is no action, suit, proceeding, inquiry or investigation brought by or before any governmental
entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which
could be expected, individually or in the aggregate, to have a Material Adverse Change or materially and adversely affect the consummation
of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder; and the aggregate
of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective
properties or assets is the subject, including ordinary routine litigation incidental to the business, if determined adversely to the
Company, could not be expected to have a Material Adverse Change. No material labor dispute with the employees of the Company or any
of its subsidiaries exists, or, to the knowledge of the Company, with the employees of any principal supplier, manufacturer, customer
or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t) <I>Intellectual
Property Rights</I>.</B> The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent
applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in
the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary
for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &ldquo;<U>Intellectual
Property</U>&rdquo;), except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change. To the Company&rsquo;s knowledge,
except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as could not reasonably
be expected, individually or in the aggregate, to have a Material Adverse Change: (i) there are no third parties who have rights to any
Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is
disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company or one or more of
its subsidiaries; and (ii) there is no infringement by third parties of any Intellectual Property. There is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company&rsquo;s rights in or to any Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim,
except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as could not reasonably
be expected, individually or in the aggregate, to have a Material Adverse Change; (B) challenging the validity, enforceability or scope
of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit,
proceeding or claim, except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change; or (C) asserting that the Company
or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described
in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any patent, trademark,
trade name, service name, copyright, trade secret or other proprietary rights of others, and, except as disclosed in the Registration
Statement, the Time of Sale Prospectus, and the Prospectus, the Company is unaware of any facts which would form a reasonable basis for
any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement pursuant
to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect.
The product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by
the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company
or any subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u) <I>All
Necessary Permits, etc</I>.</B> The Company and its subsidiaries possess such valid and current certificates, authorizations or permits
required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and
as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus (&ldquo;<U>Permits</U>&rdquo;) except where
such failure to possess any such Permit could not be expected, individually or in the aggregate, to have a Material Adverse Change. Neither
the Company nor any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings
relating to the revocation or modification of, or non-compliance with, any such Permit, except for such proceeding that could not be
expected, individually or in the aggregate, to have a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v) <I>Title
to Properties</I>.</B> The Company and its subsidiaries have good and marketable title to all of the real and personal property and other
assets reflected as owned in the financial statements referred to in Section 1(j) above (or elsewhere in the Registration Statement,
the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances,
equities, adverse claims and other defects, except as do not, individually or in the aggregate, materially and adversely affect the value
of such property to the Company and its subsidiaries and do not, individually or in the aggregate, materially and adversely interfere
with the use made of such property by the Company and its subsidiaries. The real property, improvements, equipment and personal property
held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not
material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal
property by the Company or such subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(w) <I>Tax
Law Compliance</I>.</B> The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax
returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable,
any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate
proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section
1(j) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the
Company or any of its subsidiaries has not been finally determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x) <I>Insurance</I>.
</B>Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in
such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including,
but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage,
destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and
clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew
its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may
be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to have a Material Adverse
Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has
applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(y) <I>Compliance
with Environmental Laws</I>.</B> Except as could not be expected, individually or in the aggregate, to have a Material Adverse Change:
(i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation,
ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative
order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations
relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,
petroleum or petroleum products (collectively, &ldquo;<B>Hazardous Materials</B>&rdquo;) or to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &ldquo;<B>Environmental Laws</B>&rdquo;);
(ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws
and are each in compliance with their requirements; (iii) there are no pending, or to the knowledge of the Company and its subsidiaries,
threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv) there
are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action,
suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating
to Hazardous Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(z) <I>ERISA
Compliance</I>.</B> The Company and its subsidiaries and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<B>ERISA</B>&rdquo;))
established or maintained by the Company, its subsidiaries or their &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance
in all material respects with ERISA. &ldquo;<B>ERISA Affiliate</B>&rdquo; means, with respect to the Company or any of its subsidiaries,
any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended,
and the regulations and published interpretations thereunder (the &ldquo;<B>Code</B>&rdquo;) of which the Company or such subsidiary
is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with respect
to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates.
No &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if
such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined
under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any
liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or
(ii) Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries
or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred,
whether by action or failure to act, which would cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aa) <I>Company
Not an &ldquo;Investment Company.&rdquo;</I></B> The Company is not, and will not be, either after receipt of payment for the Offered
Securities or after the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration Statement,
the Time of Sale Prospectus or the Prospectus, required to register as an &ldquo;investment company&rdquo; under the Investment Company
Act of 1940, as amended (the <B>&ldquo;Investment Company Act&rdquo;)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bb) <I>No
Price Stabilization or Manipulation; Compliance with Regulation M</I>.</B> Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares
or the Warrants, or of any &ldquo;reference security&rdquo; (as defined in Rule 100 of Regulation M under the Exchange Act (<B>&ldquo;Regulation
M&rdquo;</B>)) with respect to the Shares or the Warrants, whether to facilitate the sale or resale of the Offered Securities or otherwise,
and has taken no action which would directly or indirectly violate Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cc) <I>Related-Party
Transactions</I>.</B> There are no business relationships or related-party transactions involving the Company or any of its subsidiaries
or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not
been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(dd) <I>FINRA
Matters</I>.</B> All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel,
its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in
connection with the offering of the Offered Securities is true, complete, correct and compliant with FINRA&rsquo;s rules and any
letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete
and correct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ee) <I>Parties
to Lock-Up Agreements</I>.</B> The Company has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit
A</U> (the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each of the persons listed on <U>Exhibit B</U>. Such <U>Exhibit B</U> lists
under an appropriate caption the directors and officers of the Company and such other persons as have executed the Lock-up
Agreement. If any additional persons shall become directors or officers of the Company prior to the end of the Lock-up Period (as
defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a
director or officer of the Company, to execute and deliver to the Representative a Lock-up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ff) <I>Statistical
and Market-Related Data</I>.</B> All statistical, demographic and market-related data included in the Registration Statement, the
Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry,
to be reliable and accurate. To the extent required, the Company has obtained the written consent to the use of such data from such
sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(gg) <I>No
Unlawful Contributions or Other Payments</I>.</B> Neither the Company nor any of its subsidiaries nor, to the best of the
Company&rsquo;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any
official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be
disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hh)&#9;<I>Anti-Corruption
and Anti-Bribery Laws</I>.</B> Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer,
or employee of the Company or any of its subsidiaries, any agent, affiliate or other person acting on behalf of the Company or any of
its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken
any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or
domestic government official or employee, including of any government-owned or controlled entity or public international organization,
or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the
U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<B>FCPA</B>&rdquo;), the UK Bribery Act 2010, or any other applicable
anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe,
rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge
of the Company, the Company&rsquo;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii) <I>Money
Laundering Laws</I>.</B> The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar
applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B>Money
Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge
of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(jj) <I>Sanctions</I>. </B>Neither
the Company nor any of its subsidiaries nor, to the knowledge of the Company, after due inquiry, any director, officer, agent,
employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the
target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(&ldquo;<B>OFAC</B>&rdquo;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her
Majesty&rsquo;s Treasury of the United Kingdom, or other relevant sanctions authority (collectively,
&ldquo;<B>Sanctions</B>&rdquo;); nor is the Company or any of its subsidiaries located, organized or resident in a country or
territory that is the subject or the target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria;
and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available
such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities
of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of
Sanctions or in any other manner that will result in a violation by any person (including any person participating in the
transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company
and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person
that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any sanctioned
country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(kk) <I>Brokers</I>. </B>Except
pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or
finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ll) <I>Forward-Looking
Statements.</I></B> Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section
27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus
or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company
of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful
cautionary statements identifying those factors that could cause actual results to differ materially from those in such
forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it
was false or misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(mm) <I>Clinical
Data and Regulatory Compliance.</I></B> The preclinical tests and clinical trials, and other studies (collectively,
&ldquo;studies&rdquo;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of
Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the
protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research
procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents
the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which
are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time
of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as
may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or
from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review
Board (collectively, the &ldquo;<B>Regulatory Agencies</B>&rdquo;); neither the Company nor any of its subsidiaries has received any
notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical
trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the
Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules,
regulations and policies of the Regulatory Agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(nn) <I>No
Contract Terminations.</I></B> Neither the Company nor any of its subsidiaries has sent or received any communication regarding
termination of, or intent not to renew, any of the contracts or agreements referred to or described in any preliminary prospectus,
the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration
Statement, or any document incorporated by reference therein, and no such termination or non-renewal has been threatened by the
Company or any of its subsidiaries or, to the Company&rsquo;s knowledge, any other party to any such contract or agreement, which
threat of termination or non-renewal has not been rescinded as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(oo) <I>Cybersecurity</I></B>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted,
free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including &ldquo;Personal Data,&rdquo; used in connection with their businesses. &ldquo;<B>Personal Data</B>&rdquo;
means (i) a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or tax
identification number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account number;
(ii) any information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act,
as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR (as defined below); (iv) any information which would qualify as &ldquo;protected
health information&rdquo; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information
Technology for Economic and Clinical Health Act (collectively, &ldquo;<B>HIPAA&rdquo;</B>); and (v) any other piece of information that
allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to
an identified person&rsquo;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or
accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person,
nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material
compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal
Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(pp) <I>Compliance
with Data Privacy Laws</I></B>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all
applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and
its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and
currently are in compliance with, the European Union General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (EU 2016/679)
(collectively, the &ldquo;<B>Privacy Laws</B>&rdquo;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries
have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their
policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis
of Personal Data (the &ldquo;<B>Policies</B>&rdquo;). The Company and its subsidiaries have at all times made all disclosures to
users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained
in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or
requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of
any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no
knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or
paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is
a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters
in connection with the offering, or the purchase and sale, of the Offered Securities shall be deemed a representation and warranty by
the Company to each Underwriter as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a reasonable basis for making each of the representations set forth in this Section 1. The Company acknowledges that the
Underwriters and, for purposes of the opinions to be delivered pursuant to Section 6 hereof, counsel to the Company and counsel to the
Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2. Purchase, Sale and Delivery of the Offered Securities</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>The
Offered Securities</I>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate
of 44,700,000 Shares and 44,700,000 Warrants. On the basis of the representations, warranties and agreements herein contained, and upon
the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company
the respective number of Offered Securities set forth opposite their names on <U>Schedule</U> A. The purchase price per Share and the
accompanying one Warrant to be paid by the several Underwriters to the Company shall be $0.36075.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>The
First Closing Date</I>.</B> Delivery of the Offered Securities to be purchased by the Underwriters and payment therefor shall be made
at the offices of Covington &amp; Burling LLP, 620 Eighth Avenue, New York, NY 10018 (or such other place or in such other manner as
may be agreed to by the Company and the Representative) against payment therefor, at 9:00 a.m. New York City time, on December 21, 2021,
or such other time and date not later than 1:30 p.m. New York City time, on December 30, 2021 as the Representative shall designate by
notice to the Company (the time and date of such closing are called the &ldquo;<B>First Closing Date</B>&rdquo;). The Company hereby
acknowledges that circumstances under which the Representative may provide notice to postpone the First Closing Date as originally scheduled
include, but are not limited to, any determination by the Company or the Representative to recirculate to the public copies of an amended
or supplemented Prospectus or a delay as contemplated by the provisions of Section 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Public
Offering of the Offered Securities</I>.</B> The Representative hereby advises the Company that the Underwriters intend to offer for sale
to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their
respective portions of the Offered Securities as soon after this Agreement has been executed as the Representative, in its sole judgment,
has determined is advisable and practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
<I>Payment for the Offered Securities</I>.</B> (i) Payment for the Offered Securities shall be made at the First Closing Date
by wire transfer of immediately available funds to the order of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) It
is understood that the Representative has been authorized, for its own account and the accounts of the several Underwriters, to accept
delivery of and receipt for, and make payment of the purchase price for, the Offered Securities the Underwriters have agreed to purchase.
Cantor, individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for any Offered
Securities to be purchased by any Underwriter whose funds shall not have been received by the Representative by the First Closing Date,
for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>Delivery
of the Offered Securities</I>.</B> The Company shall deliver, or cause to be delivered to the Representative for the accounts of the
several Underwriters the Shares and Warrants in accordance with the Underwriters&rsquo; instructions, at the First Closing Date, against
release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representative so elects,
delivery of the Offered Securities may be made by credit to the account designated by the Representative through The Depository Trust
Company&rsquo;s full fast transfer or DWAC programs. If the Representative so elects, the certificates for the Offered Securities, if
any, shall be registered in such names and denominations as the Representative shall have requested at least two full business days prior
to the First Closing Date and shall be made available for inspection on the business day preceding the First Closing Date at a location
in New York City as the Representative may designate; <I>provided</I>, <I>however</I>, that if the Company, upon the instruction of the
Representative, registers the Warrants in the name of any person or entity to whom any Underwriter intends to sell such Warrants, then
such Underwriter shall have the right to thereafter request the re-registration of such Warrants (and the Company shall be required to
re-register such Warrants) in the name of any other person or entity (it being understood that such re-registration is intended to permit
an Underwriter to resell such Warrants in the event that the person or entity to whom such Underwriter originally intended to sell such
Warrants shall fail to pay the purchase price of such Warrants). Time shall be of the essence, and delivery at the time and place specified
in this Agreement is a further condition to the obligations of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3. Additional Covenants of the Company.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company further covenants and agrees with each Underwriter as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus.</I></B> The Company shall furnish to you in New York City, without
charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when
a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance
with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities, as many copies of the
Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>Representative&rsquo;s
Review of Proposed Amendments and Supplements.</I></B> During the period when a prospectus relating to the Offered Securities is required
by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), the Company (i) will furnish to the Representative for review, a reasonable period of time prior to the proposed time of filing
of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii) will not
amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under
the Exchange Act) without the Representative&rsquo;s prior written consent, which shall not be unreasonably withheld. Prior to amending
or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through
incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representative for review, a reasonable amount
of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement.
The Company shall not file or use any such proposed amendment or supplement without the Representative&rsquo;s prior written consent,
which shall not be unreasonably withheld. The Company shall file with the Commission within the applicable period specified in Rule 424(b)
under the Securities Act any prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Free
Writing Prospectuses.</I></B> The Company shall furnish to the Representative for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or
on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus
or any amendment or supplement thereto without the Representative&rsquo;s prior written consent, which shall not be unreasonably withheld.
The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf
of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by
the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule)
in connection with sales of the Offered Securities (but in any event if at any time through and including the First Closing Date) there
occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or
referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would
include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such
free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or
supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided, however</I>,
that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representative for review,
a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free
writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without
the Representative&rsquo;s prior written consent, which shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Filing
of Underwriter Free Writing Prospectuses.</I></B> The Company shall not take any action that would result in an Underwriter or the Company
being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or
on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>Amendments
and Supplements to Time of Sale Prospectus.</I></B> If the Time of Sale Prospectus is being used to solicit offers to buy the Offered
Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist
as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist
as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the
opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable
law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare, file with the Commission and furnish, at its
own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that
the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to
a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with
the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply
with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f) <I>Certain
Notifications and Required Actions</I>.</B> After the date of this Agreement, the Company shall promptly advise the Representative in
writing of: (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) the
time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii) the time and date that any post-effective
amendment to the Registration Statement becomes effective; and (iv) the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the
Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of
Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or
quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or
of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any
time, the Company will use its reasonable best efforts to obtain the lifting of such order at the earliest possible moment. Additionally,
the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430B under the Securities Act
and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a
timely manner by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g) <I>Amendments
and Supplements to the Prospectus and Other Securities Act Matters.</I></B> If any event shall occur or condition exist as a result of
which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not
misleading, or if in the opinion of the Representative or counsel for the Underwriters it is otherwise necessary to amend or supplement
the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and Section 3(c) hereof) to promptly prepare,
file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements
to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not
misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representative&rsquo;s
consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&rsquo;s obligations under
Section 3(b) or Section 3(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h) <I>Blue
Sky Compliance</I>.</B> The Company shall cooperate with the Representative and counsel for the Underwriters to qualify or register the
Offered Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial
securities laws (or other foreign laws) of those jurisdictions designated by the Representative, shall comply with such laws and shall
continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Securities.
The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service
of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.
The Company will advise the Representative promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Offered Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for
any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company
shall use its reasonable best efforts to obtain the withdrawal thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i) <I>Use
of Proceeds</I>.</B> The Company shall apply the net proceeds from the sale of the Offered Securities sold by it in the manner described
under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j) <I>Transfer
Agent</I>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k) <I>Earnings
Statement</I>.</B> The Company will make generally available to its security holders and to the Representative as soon as practicable
an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter
of the Company commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and
the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l) <I>Continued
Compliance with Securities Laws</I>.</B> The Company will comply with the Securities Act and the Exchange Act so as to permit the completion
of the distribution of the Offered Securities as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale
Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus
relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule
172 under the Securities Act or any similar rule), file on a timely basis with the Commission and the Nasdaq all reports and documents
required to be filed under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m) <I>Listing</I>. </B>The
Company will use its best efforts to list, subject to notice of issuance, the Offered Shares and the Warrant Shares on the Nasdaq
Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n) <I>Company
to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</I>.</B> If requested by the Representative, the Company
shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representative
an &ldquo;<B>electronic Prospectus</B>&rdquo; to be used by the Underwriters in connection with the offering and sale of the Offered
Securities. As used herein, the term &ldquo;<B>electronic Prospectus</B>&rdquo; means a form of Time of Sale Prospectus, and any amendment
or supplement thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to
the Representative, that may be transmitted electronically by the Representative and the other Underwriters to offerees and purchasers
of the Offered Securities; (ii) it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that
graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in
the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate;
and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representative, that will allow
investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors
(other than any fee charged for subscription to the Internet as a whole and for on-line time). The Company hereby confirms that it has
included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement
at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the
Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o) <I>Agreement
Not to Offer or Sell Additional Shares</I>.</B> During the period commencing on and including the date hereof and continuing through
and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein
as the &ldquo;<B>Lock-up Period</B>&rdquo;), the Company will not, without the prior written consent of the Representative (which consent
may be withheld in its sole discretion), directly or indirectly: (i) sell, offer to sell, contract to sell or lend any Shares or Related
Securities (as defined below); (ii) effect any short sale, or establish or increase any &ldquo;put equivalent position&rdquo; (as defined
in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any &ldquo;call equivalent position&rdquo; (as defined in Rule 16a-1(b)
under the Exchange Act) of any Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in any Shares or
Related Securities; (iv) in any other way transfer or dispose of any Shares or Related Securities; (v) enter into any swap, hedge or
similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities,
regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any Shares
or Related Securities; (vii) file any registration statement under the Securities Act in respect of any Shares or Related Securities
(other than as contemplated by this Agreement with respect to the Offered Securities); (viii) effect a reverse stock split, recapitalization,
share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix) publicly announce the intention
to do any of the foregoing; <I>provided, however</I>, that the Company may (A) effect the transactions contemplated hereby (including
issuance of the Warrants and Warrant Shares), (B) issue Shares or options to purchase Shares, or issue Shares upon exercise of options,
pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, provided that any directors or officers who are recipients thereof have provided to the Representative
a signed Lock-Up Agreement in the form of <U>Exhibit A</U> hereto, and (C) after the 60th day of the Lock-up Period, issue Shares pursuant
to the Open Market Sale Agreement, dated August 17, 2018, as amended on November 19, 2021, by and between the Company and the placement
agent named therein, as may be amended from time to time. For purposes of the foregoing, &ldquo;<B>Related Securities</B>&rdquo; shall
mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into
Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p) <I>Future
Reports to the Representative.</I></B> During the period of five years hereafter, the Company will furnish to Cantor, c/o Cantor Fitzgerald
&amp; Co., 499 Park Avenue, New York, NY 10022, (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report
of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&rsquo;
equity and cash flows for the year then ended and the opinion thereon of the Company&rsquo;s independent public or certified public accountants;
(ii) as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form 10-K, Quarterly Report on
Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission or any securities exchange; and (iii)
as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital
stock; <I>provided, however,</I> that the requirements of this Section 3(p) shall be satisfied to the extent that such reports, statement,
communications, financial statements or other documents are available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q) <I>Investment
Limitation</I>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Securities
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r) <I>No
Stabilization or Manipulation; Compliance with Regulation M</I>. </B>The Company will not take, and will ensure that no affiliate of
the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation
of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered
Securities or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation
M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s) <I>Enforce
Lock-Up Agreements</I>.</B> During the Lock-up Period, the Company will enforce all agreements between the Company and any of its security
holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the
other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct the transfer
agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &ldquo;lock-up&rdquo; agreements
for the duration of the periods contemplated in such agreements, including, without limitation, &ldquo;lock-up&rdquo; agreements entered
into by the Company&rsquo;s officers and directors and stockholders pursuant to Section 6(i) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t) <I>Company
to Provide Interim Financial Statements</I>.</B> Prior to the First Closing Date, the Company will furnish the Underwriters, as soon
as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company
for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and
the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u) <I>Warrants.
</I></B>The Company shall, at all times while any Warrants are outstanding, use its commercially reasonable best efforts to maintain
a registration statement covering the issue and sale of the Warrant Shares upon exercise of the Warrants such that the Warrant Shares,
when issued, will not be subject to resale restrictions under the Securities Act except to the extent that the Warrant Shares are owned
by affiliates. The Company shall, at all times while any Warrants are outstanding, reserve and keep available out of the aggregate of
its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares
upon exercise of such Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding
Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative, on behalf of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company of
any one or more of the foregoing covenants or extend the time for their performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4. Payment of Expenses.</B> The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of
its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses
incident to the issuance and delivery of the Offered Shares and the Warrant Shares and the execution and delivery of the Warrants (including
all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Offered Shares and Warrant Shares,
(iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Securities to the Underwriters,
(iv) all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants and other advisors, (v)
all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement
(including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus,
each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, and
all amendments and supplements thereto, and this Agreement, (vi) all filing fees, reasonable and documented attorneys&rsquo; fees and
expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification
or registration of) all or any part of the Offered Securities for offer and sale under the state securities or blue sky laws or the provincial
securities laws of Canada, and, if requested by the Representative, preparing and printing a &ldquo;Blue Sky Survey&rdquo; or memorandum
and a &ldquo;Canadian wrapper,&rdquo; and any supplements thereto, advising the Underwriters of such qualifications, registrations and
exemptions, (vii) the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the
rules and regulations of FINRA related to the Underwriters&rsquo; participation in the offering and distribution of the Offered Securities,
including any related filing fees and the reasonable and documented legal fees of, and disbursements by, counsel to the Underwriters,
such fees of counsel to the Underwriters in subclauses (vi) and (vii) not to exceed $15,000, (viii) the costs, fees and expenses of legal
counsel to the Underwriters in an amount up to $100,000, (ix) the costs and expenses of the Company relating to investor presentations
on any &ldquo;road show,&rdquo; including, without limitation, expenses associated with the preparation or dissemination of any electronic
road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in
connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives,
employees and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show,
(x) the fees and expenses associated with listing the Offered Securities on the Nasdaq, and (xi) all other fees, costs and expenses of
the nature referred to in Item 14 of Part II of the Registration Statement. Except as provided in this Section 4 or in Section 7, Section
9 or Section 10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5. Covenant of the Underwriters.</B> Each Underwriter severally and not jointly covenants with the Company not to take any action
that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the
Company under Rule 433(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6. Conditions of the Obligations of the Underwriters.</B> The respective obligations of the several Underwriters hereunder to
purchase and pay for the Offered Securities as provided herein on the First Closing Date shall be subject to the accuracy of the
representations and warranties on the part of the Company set forth in Section 1 hereof as of the date hereof and as of the First
Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to
each of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Comfort
Letter</I>.</B> On the date hereof, the Representative shall have received from Whitley Penn LLP, independent registered public accountants
for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representative,
containing statements and information of the type ordinarily included in accountant&rsquo;s &ldquo;comfort letters&rdquo; to underwriters,
delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited
financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each
free writing prospectus, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) &nbsp;<I>Compliance
with Registration Requirements; No Stop Order; No Objection from FINRA. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) &nbsp;The
Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement
pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities
Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information previously omitted
from the Registration Statement pursuant to such Rule 430B, and such post-effective amendment shall have become effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) &nbsp;No
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall
be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) &nbsp;If
a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms
and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) &nbsp;<I>No
Material Adverse Change or Ratings Agency Change</I>.</B> For the period from and after the date of this Agreement and through and including
the First Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) &nbsp;in
the judgment of the Representative there shall not have occurred any Material Adverse Change; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) &nbsp;there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company
or any of its subsidiaries by any &ldquo;nationally recognized statistical rating organization&rdquo; as that term is used in Rule 15c3-1(c)(2)(vi)(F)
under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) &nbsp;<I>Opinion
and Negative Assurance Letter of Counsel for the Company</I>.</B> On the First Closing Date, the Representative shall have received the
opinion and negative assurance letter of Morgan, Lewis &amp; Bockius LLP, counsel for the Company, dated as of such date, in the form
and substance satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) &nbsp;<I>Opinions
of Intellectual Property Counsel for the Company.</I></B> On the First Closing Date, the Representative shall have received the opinion
of each of Foley &amp; Lardner LLP and Cooley LLP, each counsel for the Company with respect to intellectual property matters, dated
as of such date, in the form and substance satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f) &nbsp;<I>Opinion
and Negative Assurance Letter of Counsel for the Underwriters</I>.</B> On the First Closing Date, the Representative shall have received
the opinion and negative assurance letter of Covington &amp; Burling LLP, counsel for the Underwriters in connection with the offer and
sale of the Offered Securities, in form and substance satisfactory to the Underwriters, dated as of such date, with executed copies for
each of the other Underwriters named on the Prospectus cover page.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g) &nbsp;<I>Officers&rsquo;
Certificate</I>.</B> On the First Closing Date, the Representative shall have received a certificate executed by the Chief Executive
Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in
Section 6(b)(ii) and further to the effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) &nbsp;for
the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse
Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) &nbsp;the
representations, warranties and covenants of the Company set forth in Section 1 of this Agreement are true and correct with the same
force and effect as though expressly made on and as of such date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) &nbsp;the
Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder
at or prior to such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h) &nbsp;<I>Bring-down
Comfort Letter</I>.</B> On the First Closing Date, the Representative shall have received from Whitley Penn LLP, independent registered
public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representative, which letter
shall: (i) reaffirm the statements made in the letter furnished by them pursuant to Section 6(a), except that the specified date referred
to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date; and (ii) cover
certain financial information contained in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i) &nbsp;<I>Lock-Up
Agreements.</I></B> On or prior to the date hereof, the Company shall have furnished to the Representative an agreement in the form of
<U>Exhibit A </U>hereto from each of the persons listed on <U>Exhibit B </U>hereto, and each such agreement shall be in full force and
effect on the First Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j) &nbsp;<I>Rule
462(b) Registration Statement</I></B>. In the event that a Rule 462(b) Registration Statement is filed in connection with the offering
contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this
Agreement and shall have become effective automatically upon such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k) &nbsp;<I>Additional
Documents</I></B>. On or before the First Closing Date, the Representative and counsel for the Underwriters shall have received such
information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale
of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties,
or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection
with the issuance and sale of the Offered Securities as contemplated herein and in connection with the other transactions contemplated
by this Agreement shall be satisfactory in form and substance to the Representative and counsel for the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any condition specified in this Section 6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representative by notice from the Representative to the Company at any time on or prior to the First Closing Date, which termination
shall be without liability on the part of any party to any other party, except that Section 4, Section 7, Section 9 and Section 10 shall
at all times be effective and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.&#9;Reimbursement of Underwriters&rsquo; Expenses</B>. If this Agreement is terminated by the Representative pursuant to Section 6,
Section 11 or Section 12, or if the sale to the Underwriters of the Offered Securities on the First Closing Date is not consummated because
of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof,
the Company agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this Agreement
with respect to themselves), severally, upon demand for all documented out-of-pocket expenses that shall have been reasonably incurred
by the Representative and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Securities,
including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone
charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.&#9;Effectiveness of this Agreement</B>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.&#9;Indemnification</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) &nbsp;<I>Indemnification
of the Underwriters</I>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers,
employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange
Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer,
employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory
law or regulation, or the laws or regulations of foreign jurisdictions where Offered Securities have been offered or sold or at common
law or otherwise (including in investigating, preparing, defending or settling any litigation, or any investigation or proceeding by
any governmental or regulatory authority, court, arbitrator or self-regulatory organization, provided that any such settlement is effected
with the written consent of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as
contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement
of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company
has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material or the
Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary
in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (iii) any act or failure
to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the Warrants
or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action
arising out of or based upon any matter covered by clause (i) or (ii) above; and to reimburse each Underwriter and each such affiliate,
director, officer, employee, agent and controlling person for any and all expenses (including the fees and disbursements of counsel)
as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection
with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided,
however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but
only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made
in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representative in writing
expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus,
any Marketing Material or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such
information consists of the information described in Section 9(b) below. The indemnity agreement set forth in this Section 9(a) shall
be in addition to any liabilities that the Company may otherwise have. &ldquo;Marketing Materials&rdquo; means any materials or information
provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Securities,
including any road show or investor presentations made to investors by the Company (whether in person or electronically).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) &nbsp;<I>Indemnification
of the Company, its Directors and Officers.</I></B> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless
the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls
the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred,
to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange
Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in investigating, preparing, defending
or settling any litigation, or any investigation or proceeding by any governmental or regulatory authority, court, arbitrator or self-regulatory
organization, provided that any such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim,
damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement
or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading
or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale
Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433
of the Securities Act or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a
material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading,
in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission
was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus or the
Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished
to the Company by the Representative in writing expressly for use therein; and to reimburse the Company, or any such director, officer
or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the
Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying
any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representative
have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus,
any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the
Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the first sentence in the third and fourth
paragraphs under the caption &ldquo;Underwriting,&rdquo; the last sentence in the fourth paragraph under the caption &ldquo;Underwriting,&rdquo;
first paragraph under the caption &ldquo;Commission and Expenses,&rdquo; and the first sentence in the first paragraph, the first and
second sentences in the second paragraph and the first sentence in the sixth paragraph under the caption &ldquo;Stabilization&rdquo;
in each case under the caption &ldquo;Underwriting&rdquo; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement.
The indemnity agreement set forth in this Section 9(b) shall be in addition to any liabilities that each Underwriter may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) &nbsp;<I>Notifications
and Other Indemnification Procedures</I>.</B> Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement
of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section
9, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not
relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is
not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability
that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party
and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to
participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice
delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof
with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include
both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise
between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there
may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the
indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and
to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the
indemnifying party to such indemnified party of such indemnifying party&rsquo;s election so to assume the defense of such action and
approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section
9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the
indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood,
however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local
counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the
indemnified parties shall be selected by the Representative (in the case of counsel for the indemnified parties referred to in Section
9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 9(b) above) or (ii) the indemnifying
party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time
after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the
indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense
of the indemnifying party and shall be paid as they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) &nbsp;<I>Settlements</I>.
</B>The indemnifying party under this Section 9 shall not be liable for any settlement of any proceeding effected without its written
consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify
the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by Section 9(c) hereof, the indemnifying party shall be liable for any settlement of
any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying
party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such
request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party
(which consent is not to be unreasonably withheld), effect any settlement, compromise or consent to the entry of judgment in any pending
or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or
could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release
of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include
an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
10.&#9;Contribution</B>. If the indemnification provided for in Section 9 is for any reason held to be unavailable to or otherwise insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any
losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities
pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company,
on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the
Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Securities pursuant
to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Securities
pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public
offering price of the Offered Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters,
on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand,
or the Underwriters, on the other hand, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section 9(c), any legal or other fees or expenses reasonably incurred by such party
in connection with investigating or defending any action or claim. The provisions set forth in Section 9(c) with respect to notice of
commencement of any action shall apply if a claim for contribution is to be made under this Section 10; <I>provided, however,</I> that
no additional notice shall be required with respect to any action for which notice has been given under Section 9(c) for purposes of
indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 10 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which
does not take account of the equitable considerations referred to in this Section 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of this Section 10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts
and commissions received by such Underwriter in connection with the Offered Securities underwritten by it and distributed to the public.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to contribute pursuant to
this Section 10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective
names on <U>Schedule A</U>. For purposes of this Section 10, each affiliate, director, officer, employee and agent of an Underwriter
and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same
rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration
Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have
the same rights to contribution as the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
11.&#9;Default of One or More of the Several Underwriters</B><I>.</I> If, on the First Closing Date any one or more of the several Underwriters
shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such date, and the aggregate
number of Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed
10% of the aggregate number of the Offered Securities to be purchased on such date, the Representative may make arrangements satisfactory
to the Company for the purchase of such Offered Securities by other persons, including any of the Underwriters, but if no such arrangements
are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Offered
Securities set forth opposite their respective names on <U>Schedule A </U>bears to the aggregate number of Offered Securities set forth
opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative with
the consent of the non-defaulting Underwriters, to purchase the Offered Securities which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date. If, on the First Closing Date any one or more of the Underwriters shall fail or
refuse to purchase Offered Securities and the aggregate number of Offered Securities with respect to which such default occurs exceeds
10% of the aggregate number of Offered Securities to be purchased on such date, and arrangements satisfactory to the Representative and
the Company for the purchase of such Offered Securities are not made within 48 hours after such default, this Agreement shall terminate
without liability of any party to any other party except that the provisions of Section 4, Section 7, Section 9 and Section 10 shall
at all times be effective and shall survive such termination. In any such case either the Representative or the Company shall have the
right to postpone the First Closing Date, but in no event for longer than seven days in order that the required changes, if any, to the
Registration Statement and the Prospectus or any other documents or arrangements may be effected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the term &ldquo;<B>Underwriter</B>&rdquo; shall be deemed to include any person substituted for a defaulting
Underwriter under this Section 11. Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability
in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
12.&#9;Termination of this Agreement</B><I>.</I> Prior to the purchase of the Offered Securities by the Underwriters on the First Closing
Date, this Agreement may be terminated by the Representative by notice given to the Company if at any time: (i) trading or quotation
in any of the Company&rsquo;s securities shall have been suspended or limited by the Commission or by the Nasdaq, or trading in securities
generally on either the Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally
established on any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of federal, New York or
Delaware authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis
or calamity, or any change in the United States or international financial markets, or any substantial change or development involving
a prospective substantial change in United States&rsquo; or international political, financial or economic conditions, as in the judgment
of the Representative is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms
described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv) in the judgment of
the Representative there shall have occurred any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire,
flood, earthquake, accident or other calamity of such character as in the judgment of the Representative may interfere materially with
the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination
pursuant to this Section 12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company shall
be obligated to reimburse the expenses of the Representative and the Underwriters pursuant to Section 4 or Section 7 hereof or (b) any
Underwriter to the Company; <I>provided, however,</I> that the provisions of Section 9 and Section 10 shall at all times be effective
and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
13.&#9;No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that (a) the purchase and sale of the Offered Securities
pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related discounts
and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters,
on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees
or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with
respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is
currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated
hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged
in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided
any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
14.&#9;Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities, agreements, representations, warranties
and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement
will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of
its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding,
will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
15.&#9;Notices</B>. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed
to the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Representative:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
    Fitzgerald &amp; Co.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">499
    Park Avenue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (212) 829-4708</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    General Counsel</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covington
    &amp; Burling LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">620
    Eighth Avenue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10018</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (646) 441-9113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Matthew T. Gehl</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1330
    Avenue of the Americas, 33rd Floor,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10019</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Edward Carr</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan,
    Lewis &amp; Bockius LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Federal Street</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston,
    MA 02110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (617) 341-7701</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    John Concannon III</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party hereto may change the address for receipt of communications by giving written notice to the others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
16.&#9;Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute
Underwriters pursuant to Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling
persons referred to in Section 9 and Section 10, and in each case their respective successors, and no other person will have any right
or obligation hereunder. The term &ldquo;<B>successors</B>&rdquo; shall not include any purchaser of the Offered Securities as such from
any of the Underwriters merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
17.&#9;Partial Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision
of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
18.&#9;Recognition of the U.S. Special Resolution Regimes. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) &nbsp;</B>In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation,
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) &nbsp;</B>In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
19.&#9;</B>For purposes of this Agreement, (A) &ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo;
in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k); (B) &ldquo;<B>Covered Entity</B>&rdquo; means any of the following:
(i) a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a
&ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered
FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C) &ldquo;<B>Default Right</B>&rdquo;
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1,
as applicable; and (D) &ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i) the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
20.&#9;Governing Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in accordance with the internal laws of
the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out
of or based upon this Agreement or the transactions contemplated hereby (&ldquo;<B>Related Proceedings</B>&rdquo;) may be instituted
in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the
State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &ldquo;<B>Specified Courts</B>&rdquo;),
and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a
judgment of any such court (a &ldquo;<B>Related Judgment</B>&rdquo;), as to which such jurisdiction is non-exclusive) of such courts
in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s address set
forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably
and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably
and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in
any such court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
21.&#9;General Provisions.</B> This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This
Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. Electronic signatures complying with the New York Electronic Signatures and Records
Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from time to time, or other applicable law will be deemed original signatures
for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission method of an executed counterpart of
this Agreement will constitute due and sufficient delivery of such counterpart. This Agreement may not be amended or modified unless
in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each
party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect
the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations
regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 9 and the contribution provisions
of Section 10, and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of
Section 9 and Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs
and its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as
contemplated by the Securities Act and the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof,
whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEONA
    THERAPEUTICS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward Carr</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
    Carr</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing Underwriting Agreement is hereby confirmed and accepted by the Representative in New York, New York as of the date first above
written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CANTOR
    FITZGERALD &amp; CO.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark Kaplan</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Kaplan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    Chief Operating Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
itself and the other several Underwriters named in <U>Schedule A</U> to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Underwriters</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of Shares to be Purchased</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of Warrants to be Purchased</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: left">Cantor Fitzgerald &amp; Co.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">26,820,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">26,820,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">A.G.P./Alliance Global Partners</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,880,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,880,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Free
Writing Prospectuses Included in the Time of Sale Prospectus</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Pricing
Information</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
44,700,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants:
Warrants to purchase 44,700,000 shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Exercise Price: $0.39 per share of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
to the Public per Share and accompanying Warrant: $0.39</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters&rsquo;
Discount per Share and accompanying Warrant: $0.02925</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
of Lock-up Agreement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors,
Officers and Others<U><BR>
Signing Lock-up Agreement </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Form
of Warrant</U><BR>
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 38; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: December 21, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on December 21, 2026 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Abeona
Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be
equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security
held in book-entry form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered
holder of this Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of
the Warrant Agency Agreement, in which case this sentence shall not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, $0.01 par value per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-3 (File No. 333-256850).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, LLC, the Company&rsquo;s transfer agent and registrar for the Common
Stock, and any successor appointed in such capacity, with a mailing address of 6201 15th Avenue, Brooklyn, N.Y. 11219, a facsimile number
of (718) 234-5001 and an email address of ReorgWarrants@astfinancial.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Agent</U>&rdquo; means the Transfer Agent and any successor warrant agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company in the offering in which this Warrant was issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (with a facsimile copy
or PDF copy to the Transfer Agent delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in the
definition of Transfer Agent above (or such other office or agency as the Company may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company)) of a duly executed facsimile copy or PDF copy submitted by
e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in
Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number
of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the
number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and
agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this
Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant
Agency Agreement, in which case this sentence shall not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$0.39</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
    =</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
    and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
    in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,
    either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of
    the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of
    the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading
    Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo;
    on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date
    of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof
    after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
    = </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
    =</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a
certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares
to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date
that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day
after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise, and, in the case of each of (i) and (iii), subject to the Company&rsquo;s
receipt of the aggregate Exercise Price (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per
Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is
a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise, and the Company shall return
all consideration paid by the Holder for such shares upon such rescission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation. To ensure
compliance with this restriction, each Holder will be deemed to represent to the Company each time it delivers a Notice of Exercise that
such Notice of Exercise has not violated the restrictions set forth in this paragraph, and the Company shall have no obligation to verify
or confirm the accuracy of such determination, provided that in making such representation, the Holder is relying on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission,
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon
election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the
Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to
apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to
such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction where the Successor Entity
(as defined below) does not have any equity security of a class that is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act and listed on a &ldquo;national securities exchange&rdquo; (as defined under Section 6 of the Exchange Act), the Company or any Successor
Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of
the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>,
that, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of
Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and
in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the
holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash,
stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms
of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of
the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to
have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental
Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model
obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation
of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S.
Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and
the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction
and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The payment
of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Business
Days of the Holder&rsquo;s election (or, if later, on the date of consummation of the Fundamental Transaction). The Company shall cause
any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e)
pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of
this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and
the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to,
and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to
the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the
Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at
its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for
the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the
holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of its Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and
for any period of time deemed appropriate by the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Warrant Agent (or, with respect to Warrants held other than in global form, the Company) shall register
this Warrant, upon records to be maintained by the Warrant Agent (or, with respect to Warrants held other than in global form, the Company)
for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company
and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise
hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant or make any cash payment to the Holder in lieu of the issuance of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019, Attention: Chief Financial
Officer, email address: [&bull;], or such other email address or address as the Company may specify for such purposes by notice to the
Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail
address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Warrant Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued
subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant
Agency Agreement, the provisions of this Warrant shall govern and be controlling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)<BR STYLE="clear: both">
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona Therapeutics
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
Abeona Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT>___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><U></U></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
Print)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Email
    Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:_____________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT>______________________</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 39px; width: 210px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1330
Avenue of the Americas, 33rd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is furnished to you in connection with the filing of a prospectus supplement, dated December 17, 2021 (the &ldquo;<U>Prospectus
Supplement</U>&rdquo;), to a Registration Statement on Form S-3, Registration No. 333-256850 (the &ldquo;<U>Registration Statement</U>&rdquo;)
filed by Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), with the Securities and Exchange Commission
(the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), with respect
to the public sale of up to 44,700,000 shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.01
per share (&ldquo;<U>Common Stock</U>&rdquo;), and warrants (the &ldquo;<U>Warrants</U>&rdquo;) to purchase up to 44,700,000 shares of
Common Stock (such shares issuable upon exercise of the Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo;), pursuant to the Underwriting
Agreement (the &ldquo;<U>Underwriting Agreement</U>&rdquo;), dated December 17, 2021 by and between the Company and Cantor Fitzgerald
&amp; Co., as representative of the underwriters named therein. The Shares are to be sold pursuant to the Prospectus Supplement and the
base prospectus included in the Registration Statement, effective as of October 22, 2021 (together with the Prospectus Supplement, the
&ldquo;<U>Prospectus</U>&rdquo;). The Underwriting Agreement is being filed as an exhibit to a Current Report on Form 8-K and will be
incorporated by reference into the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to all matters of fact (including factual conclusions and characterizations and descriptions of purpose, intention or other state of
mind), we have relied, with your permission, entirely upon written actions by the board of directors of the Company and certificates
of certain officers of the Company and have assumed, without independent inquiry, the accuracy of those certificates and written actions
by the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
counsel to the Company, in rendering the opinions hereinafter expressed, we have examined and relied upon originals or copies of such
corporate records, agreements, documents and instruments as we have deemed necessary or advisable for purposes of this opinion, including
(i) the certificate of incorporation and bylaws of the Company, (ii) the Registration Statement and the exhibits thereto filed with the
Commission, (iii) the Prospectus, (iv) the Underwriting Agreement, (v) the form of Warrant, and (vi) the written actions of the board
of directors referenced above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinions are limited solely to the Delaware General Corporation Law without regard to choice of law, to the extent that the same may
apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of events occurring,
circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed in this opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on such examination and subject to the foregoing, we are of the opinion that (i) the Shares, when issued by the Company and delivered
by the Company against receipt of the purchase price therefor as contemplated by the Underwriting Agreement, will be validly issued,
fully paid and non-assessable; (ii) when the Warrants are issued, sold and delivered in the manner and for the consideration stated in
the Registration Statement and the Prospectus, such Warrants will be valid and binding obligations of the Company, enforceable against
the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other
laws of general applicability relating to or affecting creditors&rsquo; rights and to general equity principles&#894; and (iii) the Warrant
Shares, when issued and delivered by the Company upon exercise of the Warrants in accordance with the terms thereof, will be validly
issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Company&rsquo;s Current Report on Form 8-K filed
with the Commission on December 17, 2021 (and its incorporation by reference into the Registration Statement) in accordance with the
requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and to the reference to this firm therein and under
the heading &ldquo;Legal Matters&rdquo; in the Prospectus included in the Registration Statement. In giving this consent, we do not admit
that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission
thereunder. In rendering this opinion, we are opining only as to the specific legal issues expressly set forth herein, and no opinion
shall be inferred as to any other matter or matters. This opinion is intended solely for use in connection with the issuance and sale
of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan,
Lewis &amp; Bockius LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 61px; width: 204px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK and CLEVELAND, Dec. 17, 2021 &ndash; Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy,
today announced the pricing of its underwritten public offering of 44,700,000 shares of its common stock and warrants to purchase 44,700,000
shares of its common stock at a combined offering price to the public of $0.39 per one share of common stock and one warrant to purchase
one share of common stock. The warrants have an exercise price of $0.39 per share of common stock, are exercisable immediately, and will
expire five years from the date of issuance. The aggregate gross proceeds from the offering are expected to be approximately $17.5 million,
before deducting the underwriting discounts and commissions and other offering expenses payable by Abeona. The offering is expected to
close on December 21, 2021, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. is acting as sole book-running manager for the offering, and A.G.P./Alliance Global Partners is acting as lead manager
for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
intends to use the net proceeds of the offering to fund continued clinical development of pipeline products, as well as for working capital
and corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-256850) that was filed
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on June 7, 2021 and amended on August 27, 2021 and October 19, 2021,
and was declared effective by the SEC on October 22, 2021. The offering is being made only by means of a prospectus supplement and the
accompanying prospectus, copies of which may be obtained from Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 499 Park Ave.,
4th Floor, New York, New York 10022, or by e-mail at <U>prospectus@cantor.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
securities described above have not been qualified under any state blue sky laws. This press release does not constitute an offer to
sell or the solicitation of offers to buy any securities of Abeona being offered, and shall not constitute an offer, solicitation or
sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Abeona Therapeutics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona&rsquo;s
clinical programs include EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel investigational AAV-based gene therapies for Sanfilippo syndrome
types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company&rsquo;s development portfolio also features
AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona&rsquo;s novel, next-generation AAV capsids are
being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona&rsquo;s fully integrated gene and cell therapy
cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL&trade; study and is capable of clinical and planned commercial
production of AAV-based gene therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; and similar expressions (as well as other words or expressions referencing
future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. These statements
include statements about the offering and the Company&rsquo;s intended use of proceeds generated from the offering. Actual results may
differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and
uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial
condition; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the ability to secure
licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory
approvals; the impact of changes in the financial markets and global economic conditions; risks associated with data analysis and reporting;
and other risks as may be detailed from time to time in the Company&rsquo;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the
forward-looking statements or to update them to reflect events or circumstances occurring after the date of this release, whether as
a result of new information, future developments or otherwise, except as required by the federal securities laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
and Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greg
Gin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP,
Investor Relations and Corporate Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
(646) 813-4709</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ggin@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ] ,P# 2(  A$! Q$!_\0
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M)N]F$)/F<66Z***HU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM^5PZGW!'UI+W3GNI5DCN6B*KM*E%=3[X/?WIMII$=LLF^1I'D?>S !!G '
*''0"C6XO?YC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 1H# 2(  A$! Q$!_\0
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M:I<VLO56Z@]B#U!'J*^0OB)X7L/"GB>XT_3Y)V@1OE\Y@Q'X@"BB@#T_X'>
M="OHAXAO(I+B\MW'DI(P,:-V;;CDCW)KZ HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "HK>WAM+6*VMXUCAA01QHO15 P /P
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abeo-20211217.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauCubP9z5Z8aekhvWB3benqbyUsGF6eESUwSQjW8UsI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ABEO="http://abeonatherapeutics/20211217" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics/20211217">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abeonatherapeutics/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20211217_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20211217_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abeo-20211217_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abeo-20211217_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics/role/Cover" xlink:href="abeo-20211217.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abeo-20211217.xsd" xlink:type="simple"/>
    <context id="From2021-12-17to2021-12-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2021-12-17</startDate>
            <endDate>2021-12-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-12-17to2021-12-17">0000318306</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-12-17to2021-12-17">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-12-17to2021-12-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-12-17to2021-12-17">2021-12-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-12-17to2021-12-17">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-12-17to2021-12-17">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-12-17to2021-12-17">001-15771</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-12-17to2021-12-17">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-12-17to2021-12-17">1330 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-12-17to2021-12-17">33rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-12-17to2021-12-17">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-12-17to2021-12-17">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-12-17to2021-12-17">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-12-17to2021-12-17">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-12-17to2021-12-17">813-4701</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-12-17to2021-12-17">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-12-17to2021-12-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-12-17to2021-12-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-12-17to2021-12-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-12-17to2021-12-17">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-12-17to2021-12-17">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-12-17to2021-12-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-12-17to2021-12-17">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140266785580520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 17,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA
THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1330
Avenue of the Americas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">33rd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
M]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NX
MZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#
MS"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;
M9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'
MGL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G
M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" #<BI%3EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    " #<BI%3!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -R*D5-U
M9,+)[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( -R*D5.97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ W(J14YQ=@)%0!
MV1   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( -R*D5.?H!OPL0(  .(,   -              "  90,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ W(J14Y>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>abeo-20211217.xsd</File>
    <File>abeo-20211217_lab.xml</File>
    <File>abeo-20211217_pre.xml</File>
    <File>ex1-1.htm</File>
    <File>ex4-1.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20211217_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20211217_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abeo-20211217.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABEO",
   "nsuri": "http://abeonatherapeutics/20211217",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-12-17to2021-12-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abeonatherapeutics/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-12-17to2021-12-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-21-031904-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-031904-xbrl.zip
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M +O))@5-34 D6(T!-!RT^3.E7HB8R9%)8#IG,=G]3/9@NUHZMTP -IM0&**
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M<Y4PS*($TRH]HNV*>'^(,UH&FJ_ Z=&'P= PDRV<BC"=R[ */*2Z='TIO7@
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M>&ULS9Q-<]LV$(;OG>E_8-6S)$MNF]JQF[$5*Z.)$[N6D[2]9" 2DC & 0T
M6M*_+T"*BCX(<'WAV@=;IA; OL^"()< >/%NE?+HF2K-I+AL]3HGK8B*6"9,
MS"Y;7\;MJ_%@-&I%VA"1$"X%O6P)V7KWU\\_1?;GXI=V.QHRRI/SZ+V,VR,Q
ME6^CSR2EY]$'*J@B1JJWT5?",W=$#AFG*AK(=,&IH?:+HN'SZ/=.[R2.VFU
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MT:]K,OV^QQ>)@?@L^C]8YP!__I^6<=HUUV*65!?S6?1ALX91G%;)+)L_B]Z
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M@]<C,0F)*TPGWKF\A1##(,V(IV0G_"3W;I0 &\P?*>$:]7S(^:MUN<([7O!
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M$65SXKU/*M0<_HW/&-C+:[ZV-;=FQ8/7L3(D***O'4J;='P)B.@^R2KJZDY
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M)891G6W+G3I7F33T->4F0>!7<U[8H%+%S.Y8K"X CXJV=_L<7/LL,!SF&6&
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M?>;3=M@3@,'8P[D%H3*OHI@$I2ZN+_.G[=BG;A",PD_A2VR08 WF29T*#B6
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MZ9MI*A_D]"J8 W[EY>6JSCFO>'5>2IM.RM 5#_*LX%</=B96&*C'JIYC&^F
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M 9_L78V?R_G%@W8=O:5'&Q_C<*" !LQ0?W=Q0'V ]FD$URWI _G0="*&OE)
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MT,.&8?WWR3?Q\?%QK!4%6_<:7DO30!34UK<C0'B%%QDXA?B9_SZ!5_!KL#S
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MS.0>J!0;'_OF""Y(CFWJ16"U,@?*7J$;:GZM8=F<;U6T\WXO,^KYX0.EMB*
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M:2E/";<AL< YXOD4CJS9(5=/8ZO+MFJ$-=1\$4,%^RCJG0I:^"@J*;.A2/I
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MX1$[KDH#A8I+?$%+8&!1.AS;ZEO3W'A[#6Y,8"3VV<4^-0Q#VG;1>&95T!Q
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M,F4O3N <$=RV*#F#ZTYGX3*GHJ;QB6.-T42U!$!'.5MBQDV Z25NDV!YEUH
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MZ!@/;/E46Q!^0(D7AM#;6<\3!$KIXB,^E=KGZG)C'ZH+494_'2580<2;FLD
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MO-U\RT>;?,N[F6]Y-R[ZYWL[.MP=^&OGN>QP=KQJN.U5?7P;B8!SZ[5V)>U
M)&T+B[/81D,!IHJW*:[@ 0J:L8+ ]FV4+URD#7>K<2!K_,*' X,*<SZQNJ8
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MXQ!+5B5^V%<H+.W2V]U7;%8!Z$\.9-EK&ZLP;-)'>RZ0&H0C8TN6L(5.%^6
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M A5@XU4^[$[09"+',UEF56%CBGX[VV?4&B.M?$"),&2ELA.U)V[B:$>;7O)
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M4)"1G!^;^MR8MM3Y73(X(K:*SQZK='+N14<X%3FAG!-0QADBWZ295+SXV9W
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M)KRCXO2.,8XO[BU]Y+RE/Z<5FO\<0M[X2>\T,28VV]SVPP*N<.3S]:(/U&/
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M%     @ W(J14[]\;R.9"@  8#    D   !E>#4M,2YH=&WM6VMOVS@6_2Y
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ME0LT3J&24<G-D83S-(V]ZNAX2[;A(8I[RM7<P[#RW0:")I4>Q,VF,IR"_IR
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MSOT]:,7]K,R\967F:=>1GW=F,O-E818T\?4;[YA;FY2HTB5%G3K.@Z;)XT.
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M96\M,C R,3$R,3<N>'-D4$L! A0#%     @ W(J14V+W!2[]"@  @(8  !4
M             ( !9 ,  &%B96\M,C R,3$R,3=?;&%B+GAM;%!+ 0(4 Q0
M   ( -R*D5/)N.)86@<  .%7   5              "  90.  !A8F5O+3(P
M,C$Q,C$W7W!R92YX;6Q02P$"% ,4    " #<BI%3.N _$4F?  #C] , "0
M            @ $A%@  97@Q+3$N:'1M4$L! A0#%     @ W(J14Z!W6XW4
M3P  ?_X!  D              ( !D;4  &5X-"TQ+FAT;5!+ 0(4 Q0    (
M -R*D5._?&\CF0H  & P   )              "  8P% 0!E>#4M,2YH=&U0
M2P$"% ,4    " #<BI%35(JKAK,,  !L,@  "@              @ %,$ $
M97@Y.2TQ+FAT;5!+ 0(4 Q0    ( -R*D5,-@ZP6Q!4  &&7   +
L      "  2<= 0!F;W)M."UK+FAT;5!+!08     "  ( -L!   4,P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
